UK approves Pfizer and Biontech coronavirus vaccine, to be available from next week
|The Medicines and Healthcare Products Regulatory Agency (MHRA), the UK’s medical regulator, gave a green signal to the coronavirus vaccine co-developed by BioNTech SE and Pfizer Inc on Wednesday, concluding it’s both safe and effective.
The vaccine will be available in the UK from next week.
The UK joint committee confirmed the approval of the vaccine, adding that they will shortly publish its final advice for the vaccine distribution.
The Health Minister Matt Hancock was quick to respond, “this is fantastic news from the regulator on the Pfizer vaccine.”
Additional comments
“NHS stands ready, will start vaccinating next week.”
“This will be a challenging rollout due to specifics of storage.”
“We have plans in place to deal with those specifics.”
“We're expecting millions of doses for the whole of the UK by the end of the year.”
Market reaction
The above announcement was well-anticipated and failed to have any big market-moving impact. Although the S&P 500 futures trimmed losses while GBP/USD held onto mild gains around 1.3420.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.